Novo Nordisk (NVO) may see a post-earnings dip as Q4 includes conservative 2026 guidance despite oral Wegovy momentum. Click here to read my most recent analysis.
Novo Nordisk: Investors May Be In For An Earnings Surprise
Novo Nordisk (NVO) may see a post-earnings dip as Q4 includes conservative 2026 guidance despite oral Wegovy momentum. Click here to read my most recent analysis.
